PURPOSE: Metformin, an antihyperglycemic agent, is eliminated by tubular secretion in addition to glomerular filtration in the human kidney. This study was performed to characterize metformin transport by human organic cation transporter 2 (hOCT2), the most abundant organic cation transporter in the basolateral membranes of the human kidney. METHODS: Accumulation of [14C]metformin was assessed by the tracer experiments in the human embryonic kidney (HEK293) cells expressing hOCT2. RESULTS: The transport of [14C]metformin was markedly stimulated in hOCT2-expressing cells compared with the vector-transfected cells. The accumulation of [14C]metformin was concentrative and was dependent on the membrane potential, showing consistency with the characteristics of hOCT2. The apparent Km and Vmax values of [14C]metformin transport by hOCT2-expressing HEK293 cells were 1.38+/-0.21 mM and 11.9+/-1.5 nmol mg protein(-1) min(-1), respectively. The order of the potencies of unlabeled biguanides to inhibit [14C]metformin transport by hOCT2 was phenformin > buformin > metformin. Furthermore, [14C]metformin transport was inhibited slightly or moderately by cationic drugs such as procainamide and quinidine at respective therapeutic concentrations. CONCLUSIONS: Metformin is transported by the basolateral organic cation transporter hOCT2 in the human kidney. hOCT2 could play a role in the drug interactions between metformin and some cationic drugs.
PURPOSE:Metformin, an antihyperglycemic agent, is eliminated by tubular secretion in addition to glomerular filtration in the human kidney. This study was performed to characterize metformin transport by humanorganic cation transporter 2 (hOCT2), the most abundant organic cation transporter in the basolateral membranes of the human kidney. METHODS: Accumulation of [14C]metformin was assessed by the tracer experiments in the humanembryonic kidney (HEK293) cells expressing hOCT2. RESULTS: The transport of [14C]metformin was markedly stimulated in hOCT2-expressing cells compared with the vector-transfected cells. The accumulation of [14C]metformin was concentrative and was dependent on the membrane potential, showing consistency with the characteristics of hOCT2. The apparent Km and Vmax values of [14C]metformin transport by hOCT2-expressing HEK293 cells were 1.38+/-0.21 mM and 11.9+/-1.5 nmol mg protein(-1) min(-1), respectively. The order of the potencies of unlabeled biguanides to inhibit [14C]metformin transport by hOCT2 was phenformin > buformin > metformin. Furthermore, [14C]metformin transport was inhibited slightly or moderately by cationic drugs such as procainamide and quinidine at respective therapeutic concentrations. CONCLUSIONS:Metformin is transported by the basolateral organic cation transporter hOCT2 in the human kidney. hOCT2 could play a role in the drug interactions between metformin and some cationic drugs.
Authors: V Gorboulev; J C Ulzheimer; A Akhoundova; I Ulzheimer-Teuber; U Karbach; S Quester; C Baumann; F Lang; A E Busch; H Koepsell Journal: DNA Cell Biol Date: 1997-07 Impact factor: 3.311
Authors: C R Sirtori; G Franceschini; M Galli-Kienle; G Cighetti; G Galli; A Bondioli; F Conti Journal: Clin Pharmacol Ther Date: 1978-12 Impact factor: 6.875
Authors: Michael Z Liao; Shannon K Flood Nichols; Mahmoud Ahmed; Shannon Clark; Gary D Hankins; Steve Caritis; Raman Venkataramanan; David Haas; Sara K Quinney; Laura S Haneline; Alan T Tita; Tracy Manuck; Joanne Wang; Kenneth E Thummel; Linda Morris Brown; Zhaoxia Ren; Thomas R Easterling; Mary F Hebert Journal: Drug Metab Dispos Date: 2020-01-24 Impact factor: 3.922
Authors: Mackenzie C Bergagnini-Kolev; Mary F Hebert; Thomas R Easterling; Yvonne S Lin Journal: Drug Metab Dispos Date: 2017-01-09 Impact factor: 3.922
Authors: Hélène M Faessel; R Scott Obach; Hans Rollema; Patanjali Ravva; Kathryn E Williams; Aaron H Burstein Journal: Clin Pharmacokinet Date: 2010-12 Impact factor: 6.447
Authors: M Joerger; R H N van Schaik; M L Becker; S Hayoz; M Pollak; R Cathomas; R Winterhalder; S Gillessen; C Rothermundt Journal: Prostate Cancer Prostatic Dis Date: 2015-03-10 Impact factor: 5.554
Authors: Matthijs L Becker; Loes E Visser; Ron H N van Schaik; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker Journal: Diabetes Date: 2009-02-19 Impact factor: 9.461